These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 38392966)

  • 21. N6-methyladenosine RNA modification and its interaction with regulatory non-coding RNAs in colorectal cancer.
    Ge Y; Liu T; Wang C; Zhang Y; Xu S; Ren Y; Feng Y; Yin L; Pu Y; Liang G
    RNA Biol; 2021 Nov; 18(sup2):551-561. PubMed ID: 34674600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interplay between m6A RNA methylation and noncoding RNA in cancer.
    Ma S; Chen C; Ji X; Liu J; Zhou Q; Wang G; Yuan W; Kan Q; Sun Z
    J Hematol Oncol; 2019 Nov; 12(1):121. PubMed ID: 31757221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment.
    Zhang Y; Zhan L; Li J; Jiang X; Yin L
    Aging (Albany NY); 2023 May; 15(9):3857-3889. PubMed ID: 37178254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC.
    Cheng W; Li M; Zhang L; Zhou C; Yu S; Peng X; Zhang W; Zhang W
    Front Pharmacol; 2022; 13():973116. PubMed ID: 36120320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel insights into the interplay between m
    Yi YC; Chen XY; Zhang J; Zhu JS
    Mol Cancer; 2020 Aug; 19(1):121. PubMed ID: 32767982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-coding RNA-Mediated N6-Methyladenosine (m
    Hashemi M; Daneii P; Zandieh MA; Raesi R; Zahmatkesh N; Bayat M; Abuelrub A; Khazaei Koohpar Z; Aref AR; Zarrabi A; Rashidi M; Salimimoghadam S; Entezari M; Taheriazam A; Khorrami R
    Noncoding RNA Res; 2024 Mar; 9(1):84-104. PubMed ID: 38075202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research progress of N6-methyladenosine in colorectal cancer: A review.
    Lin Y; Shi H; Wu L; Ge L; Ma Z
    Medicine (Baltimore); 2023 Nov; 102(47):e36394. PubMed ID: 38013272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between m6A methylation and noncoding RNA in glioma.
    Tao N; Wen T; Li T; Luan L; Pan H; Wang Y
    Cell Death Discov; 2022 Jun; 8(1):283. PubMed ID: 35688823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers.
    Dai XY; Shi L; Li Z; Yang HY; Wei JF; Ding Q
    Front Oncol; 2021; 11():635329. PubMed ID: 33928028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N6-methyladenine modification in noncoding RNAs and its function in cancer.
    Yang X; Hu X; Liu J; Wang R; Zhang C; Han F; Chen Y; Ma D
    Biomark Res; 2020 Nov; 8(1):61. PubMed ID: 33292652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA N6-methyladenosine methylation and skin diseases.
    Yu Y; Lu S; Jin H; Zhu H; Wei X; Zhou T; Zhao M
    Autoimmunity; 2023 Dec; 56(1):2167983. PubMed ID: 36708146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crosstalk Between m6A RNA Methylation and miRNA Biogenesis in Cancer: An Unholy Nexus.
    Jayasree PJ; Dutta S; Karemore P; Khandelia P
    Mol Biotechnol; 2024 Nov; 66(11):3042-3058. PubMed ID: 37831403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Liu X; Xie X; Sui C; Liu X; Song M; Luo Q; Zhan P; Feng J; Liu J
    Int J Cancer; 2024 Jun; 154(11):1877-1889. PubMed ID: 38429857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy.
    Diao MN; Zhang XJ; Zhang YF
    Br J Cancer; 2023 Jul; 129(1):8-23. PubMed ID: 36997662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Function and prognostic value of N6-methyladenosine-modified RNAs in lung adenocarcinoma.
    Liu J; Zheng Z; Zhong J
    J Gene Med; 2023 Jan; 25(1):e3454. PubMed ID: 36282144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noncoding RNAs Associated with PPARs in Etiology of MAFLD as a Novel Approach for Therapeutics Targets.
    Kazeminasab F; Baharlooie M; Ghaedi K
    PPAR Res; 2022; 2022():6161694. PubMed ID: 36164476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The functions of N6-methyladenosine modification in lncRNAs.
    He RZ; Jiang J; Luo DX
    Genes Dis; 2020 Dec; 7(4):598-605. PubMed ID: 33335959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptome-wide profiling identifies colon cancer-associated m6A transcripts and potential RNA methyl modifiers.
    Ramasamy D; Thippannah M; Maharajan HRP; Balaiah M; Seshadri RA; Kodous AS; Herceg Z; Mehta A; Rao AKDM; Mani S
    Mol Biol Rep; 2024 Feb; 51(1):299. PubMed ID: 38345740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N6-methyladenosine (m6A) methylation in kidney diseases: Mechanisms and therapeutic potential.
    Sun Y; Jin D; Zhang Z; Ji H; An X; Zhang Y; Yang C; Sun W; Zhang Y; Duan Y; Kang X; Jiang L; Zhao X; Lian F
    Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194967. PubMed ID: 37553065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of N-methyladenosine modification in acute and chronic kidney diseases.
    Qi S; Song J; Chen L; Weng H
    Mol Med; 2023 Dec; 29(1):166. PubMed ID: 38066436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.